-
Mashup Score: 0EHA2023 - Presentation Detail - 12 month(s) agoSource: congress-apps.ehaweb.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2Engineered CAR T Cells Locally Deliver Blocker of CD47 Pathway | ASH Clinical News | American Society of Hematology - 1 year(s) ago
Skip Nav Destination April 11, 2023 Ruth Jessen Hickman, MD, is a freelance medical and science writer based in Bloomington, Indiana. Chimeric antigen receptor (CAR) T-cell therapy has demonstrated high response rates in patients…
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
To combat relapse rates associated with #CAR #Tcell therapy, researchers have engineered "Orexi” CAR T cells to locally secrete CV1, a high-affinity CD47 blocker, at the tumor site, combining treatment with an orthogonally targeted #monoclonal #antibody https://t.co/FCWGIL8Wf6
-
-
Mashup Score: 0Wolters Kluwer Health - 1 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Hundreds of clinical trials involving #CAR-T cells are ongoing worldwide, with six CAR T-cell therapies now approved by the #FDA. However, concerns remain over its high cost, variable product quality, and product manufacturing and delivery logistics. https://t.co/DixZfiVUOZ https://t.co/HOe1jrEk4Q
-
-
Mashup Score: 1Wolters Kluwer Health - 1 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Hundreds of clinical trials involving #CAR-T cells are ongoing worldwide, with six CAR T-cell therapies now approved by the #FDA. However, concerns remain over its high cost, variable product quality, and product manufacturing and delivery logistics. https://t.co/DixZfiVUOZ https://t.co/5L9ziRcJnT
-
-
Mashup Score: 0ONS Landing Page - 1 year(s) ago
null
Source: www.gotoper.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Get ready for practice-changing CE dinner & dessert sessions at the 2023 #ONSCongress! Topics include #MPN, #CAR-T, #NSCLC, #melanoma and #breastcancer. Sign up now: https://t.co/RN2RFd26EW #gotoPER #lcsm #bcsm @mazo_md @drashish2005 @mcquadeMDLAc @MarkFariesMD @AYACOUB7 https://t.co/iyfqrLyfWp
-
-
Mashup Score: 0CAR T-Cell Therapy Feasible, Safe in Advanced Neuroblastoma - 1 year(s) ago
ORR of 63% with GD2-targeting product in kids with relapsed, refractory high-risk disease
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet-
#Immunotherapy with a #CAR T-cell treatment targeting #GD2 may have a sustained #antitumor effect in at least a proportion of #pediatric patients with relapsed or refractory high-risk #neuroblastoma, as well as a favorable safety profile. #OncoTwitter https://t.co/RVDeJL4ro9
-
-
Mashup Score: 1Longitudinal Patient-reported Outcomes in Patients Receiving Chimeric Antigen Receptor T-Cell Therapy - 1 year(s) ago
Key Points. QOL and depression worsened early post CAR-T but QOL, psychological distress, and physical symptoms improved by 6 months post CAR-T.A significant mi
Source: American Society of HematologyCategories: General Medicine News, Latest HeadlinesTweet-
Breakthrough #CAR-T #cancer treatments are boosting patients' quality of life @BloodAdvances https://t.co/m0r0jGjak7 https://t.co/gbB2Ze1X2r
-
-
Mashup Score: 8Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia - Nature Biotechnology - 1 year(s) ago
A single-cell screening approach identifies targets for CAR-T cells in acute myeloid leukemia.
Source: NatureCategories: General Medicine News, Latest HeadlinesTweet-
New targets for #CAR-Tcelltherapy against #acutemyeloidleukemia through AI-assisted analysis @NatureBiotech https://t.co/C5CjVkmm24 https://t.co/oSz2OdrKOg
-
-
Mashup Score: 0Study Characterizes Enhanced Functionality of Low-Affinity CD19 CAR T-Cell Products | ASH Clinical News | American Society of Hematology - 1 year(s) ago
Skip Nav Destination January 26, 2023 Enhanced functionality of low-affinity T cells expressing a chimeric antigen receptor (CAR) targeting CD19 (CAT) is a result of an antigen-dependent priming caused by residual CD19-expressing…
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
The enhanced functionality of low-affinity #Tcells expressing a #CAR targeting #CD19 is a result of an antigen-dependent priming caused by residual CD19-expressing B cells present in the manufacture, according to a recent @BloodAdvances study https://t.co/jVbSqQIuaZ
-
-
Mashup Score: 0Dual targeting of CD19 and CD22 with Bicistronic CAR-T cells in Patients with Relapsed/Refractory Large B Cell Lymphoma - 1 year(s) ago
Key Points. AUTO3 +/- Pembrolizumab for r/r LBCL was safe, lending itself to outpatient administrationAUTO3 +/- Pembrolizumab delivered durable remissions in 54
Source: American Society of HematologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Dual targeting of CD19 and CD22 with Bicistronic #CAR-T cells in Patients with Relapsed/Refractory LBCL #CART #CellTherapy https://t.co/nvrWo8UrNM
-
Curious about #CAR-T? Join our interactive, open-table discussion on CAR T-cell therapy at #EHA2023! 🟣Ulrich Jäger (Chair) 🟣Kieron Dunleavy 🟣Shaji Kumar 🟣Doris Hansen 🟣Michael Hudecek visit our page: https://t.co/7S6OhMPHiL https://t.co/S9ZelmHQJz